Faron Pharmaceuticals: Positive phase II BEXMAB topline results - Redeye

Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint in treatment-resistant high-risk MDS. We are encouraged to see topline results confirming earlier interim data, with sustained high response rates in this difficult-to-treat population and a continued strong safety profile. These findings not only validate bexmarilimab’s clinical potential but also support Faron’s regulatory and commercial strategy as the company prepares for pivotal phase III development.

Länk till analysen i sin helhet: https://www.redeye.se/research/1095390/faron-pharmaceuticals-positive-phase-ii-bexmab-topline-results?utm_source=finwire&utm_medium=RSS